Abstract Number: Esoc2026a1224 Neuroaid for Stroke Recovery: Real-World Evidence From the Nest Registry

Abstract Background and aims NeuroAiD is a Traditional Chinese Medicine used in stroke recovery, and is available in two formulations, MLC601 and MLC901. Both have been evaluated in controlled clinical trials. To assess real-world use, the NeST Registry was established as a prospective registry with safety monitoring and standardised baseline and follow-up assessments. The NeST protocol has been previously published (NCT0253607). Methods This analysis includes NeST participants diagnosed with stroke who were treated with NeuroAiD and had baseline data plus ≥1 follow-up. Safety parameters assessed include the frequency of AEs/SAEs and discontinuation of NeuroAiD intake. Efficacy parameters include longitudinal changes in NIHSS, GCS, mRS, and cognitive performance (SOMCT) at baseline and visits 1, 2, and 3, with additional visits as deemed necessary by the attending physician. Results An overall analysis of 859 stroke patients recruited in NeST will be presented, including patients with ischemic or haemorrhagic stroke. Baseline characteristics of these patients will be presented, along with their efficacy and safety outcomes. Subgroup analyses will be conducted, including exploration of several factors (age, gender, type and severity of stroke, comorbidities, concomitant therapies, treatment adherence, etc.) Conclusions NeST provides structured real-world evidence on the efficacy and safety of NeuroAiD for post-stroke recovery, complementing numerous published clinical trials. It adds to the post-marketing surveillance data obtained through the pharmacovigilance of NeuroAiD, which has been used by thousands of patients in more than 40 countries. Conflict of interest Dr Narayanaswamy Venketasubramanian: nothing to disclose